Article
Hematology
David Spirk, Tim Sebastian, Stefano Barco, Martin Banyai, Juerg H. Beer, Lucia Mazzolai, Thomas Baldi, Drahomir Aujesky, Daniel Hayoz, Rolf P. Engelberger, Thomas Kaeslin, Wolfgang Korte, Robert Escher, Marc Husmann, Marc Blondon, Nils Kucher
Summary: In patients with cancer-associated venous thromboembolism (VTE), the risk of recurrence is similar after incidental and symptomatic events. It is unknown whether the same applies to incidental VTE not associated with cancer. After comparing baseline characteristics, anticoagulation therapy, all-cause mortality, and VTE recurrence rates at 90 days between patients with incidental and symptomatic VTE, the study found that receiving anticoagulation therapy for at least 3 months was associated with lower mortality and recurrence rates in patients with incidental VTE regardless of cancer status. Additionally, among noncancer patients, early mortality and recurrence rates were similar after incidental versus symptomatic VTE.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Cardiac & Cardiovascular Systems
Anne Gulbech Ording, Peter Bronnum Nielsen, Flemming Skjoth, Thure Filskov Overvad, Simon Noble, Timothy L. Lash, Samuel Zachery Goldhaber, Thomas Decker Christensen, Torben Bjerregaard Larsen, Mette Sogaard
Summary: This study describes the risk of recurrent venous thromboembolism in patients with active cancer and highlights the variations in recurrence risks based on cancer type and patient characteristics.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Yuichiro Okushi, Kenya Kusunose, Yoshihiro Okayama, Robert Zheng, Michikazu Nakai, Yoko Sumita, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata
Summary: Patients with cancer-associated VTE have higher in-hospital mortality rates than those without cancer, especially in pancreatic, biliary tract, and liver cancers.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Hematology
Florian Moik, Gerald Prager, Johannes Thaler, Florian Posch, Sarah Wiedemann, Theresa Schramm, Cornelia Englisch, Nigel Mackman, Ingrid Pabinger, Cihan Ay
Summary: The occurrence of VTE in pancreatic cancer patients is associated with shorter overall survival and progression-free survival. Higher levels of D-dimer, extracellular vesicle-tissue factor activity, PAI-1, and sP-selectin are independently prognostic for increased mortality. Furthermore, D-dimer can predict response to palliative chemotherapy.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2021)
Article
Oncology
F. Couturaud, I. Mahe, J. Schmidt, J-C. Gleize, T. Lafon, A. Saighi, F. Sedjelmaci, L. Bertoletti, P. Mismetti
Summary: This study aimed to provide data on the number of hospitalized VTE events among cancer patients with different types of cancer and their hospital management, and to estimate the burden of disease and the hospital burden of cancer-related VTE. The findings offer guidance on future research on VTE prophylaxis in patients with active cancer.
Article
Hematology
Yasuo Ohashi, Masataka Ikeda, Hideo Kunitoh, Mitsuru Sasako, Takuji Okusaka, Hirofumi Mukai, Keiichi Fujiwara, Mashio Nakamura, Mari S. Oba, Tetsuya Kimura, Kei Ibusuki, Atsushi Takita, Masato Sakon
Summary: This study aimed to investigate the relationship between solid tumors and venous thromboembolism (VTE) in Japanese patients. The results showed a low incidence of symptomatic VTE, but the presence of symptomatic or asymptomatic VTE at baseline was an important risk factor for developing symptomatic VTE, bleeding events, and death.
THROMBOSIS RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Maria Barca-Hernando, Sergio Lopez-Ruz, Samira Marin-Romero, Teresa Elias-Hernandez, Remedios Otero-Candelera, Luis Jara-Palomares
Summary: This study aimed to compare the rate of complications between cancer patients with incidental and symptomatic VTE through long-term follow-up. The results showed that there were no significant differences in the rate of recurrent VTE and clinically relevant bleeding between patients with incidental and symptomatic VTE. However, at six-month follow-ups, patients with incidental VTE had a higher cumulative incidence of clinically relevant bleeding than those with symptomatic VTE.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Review
Hematology
Johnathon Gorman, Matteo Candeloro, Sam Schulman
Summary: This study retrospectively analyzed all cases of VTE diagnosed during hospitalization for spontaneous ICH at our center over a 15-year period. The results showed that prompt therapeutic anticoagulation for acute VTE seems safe when occurring more than 14 days after spontaneous ICH. For VTE occurring earlier, stepwise dose escalation to therapeutic within a 7-day period might be preferable.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Biochemistry & Molecular Biology
Vasiliki Danilatou, Stylianos Nikolakakis, Despoina Antonakaki, Christos Tzagkarakis, Dimitrios Mavroidis, Theodoros Kostoulas, Sotirios Ioannidis
Summary: This study aims to develop and validate interpretable machine learning models for predicting early and late mortality in ICU patients with venous thromboembolism and/or cancer. Retrospective data from two databases were used, and the study found that ML models showed excellent performance in predicting early mortality but lower performance in predicting late mortality.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Obstetrics & Gynecology
Alexander M. Friedman, Mary E. D'Alton
Summary: Venous thromboembolism is a significant contributor to maternal mortality in the United States, with the overall maternal mortality rate increasing in recent years, likely leading to an increased risk of venous thromboembolism. Experts suggest that improving clinical care is necessary to reduce this risk, and enhancing prophylaxis and prevention may provide the greatest benefit. However, there is controversy on the best approach to improve prophylaxis, with concerns over safety, efficacy, and cost.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Hematology
Ximena Jordan Bruno, Insu Koh, Pamela L. Lutsey, Robert F. Walker, Nicholas S. Roetker, Katherine Wilkinson, Nicolas L. Smith, Timothy B. Plante, Allen B. Repp, Chris E. Holmes, Mary Cushman, Neil A. Zakai
Summary: This study aimed to evaluate the rates and risks of VTE during and up to 3 months after medical and surgical hospitalizations. The results showed a significant increase in VTE risk during hospitalization and in the first month after discharge, which then gradually decreased over time.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Immunology
Stephen Mac, Scott Shi, Brad Millson, Ali Tehrani, Masha Eberg, Varun Myageri, Joanne M. Langley, Scott Simpson
Summary: This study investigated the incidence, healthcare resource use, and associated costs of adults hospitalized with RSV in Ontario, Canada. The findings revealed an increasing trend of RSV hospitalizations in adults, which were associated with higher healthcare costs.
Article
Oncology
Helene Helfer, Yara Skaff, Florent Happe, Sadji Djennaoui, Jean Chidiac, Geraldine Poenou, Marc Righini, Isabelle Mahe
Summary: The current recommended VTE diagnostic approach is less satisfactory in cancer patients due to their nonspecific VTE symptoms and increased D-dimer levels associated with the tumor process. Several approaches have been developed to improve VTE exclusion in cancer patients, but there is still a lack of a dedicated diagnostic algorithm for this population.
Article
Hematology
Carmen Fernandez-Capitan, Raquel Barba, Maria del Carmen Diaz-Pedroche, Patricia Siguenza, Pablo Demelo-Rodriguez, Carmine Siniscalchi, Jose Maria Pedrajas, Ana I. Farfan-Sedano, Pavel Eduardo Olivera, Covadonga Gomez-Cuervo, Pilar Llamas, Paula Villares, Olivier Sanchez, Raquel Lopez-Reyes, Judith Catella, Behnood Bikdeli, Ido Weinberg, Alfonso J. Tafur, David Jimenez, Manuel Monreal
Summary: This study investigated the characteristics, treatment patterns, and short-term outcomes of patients diagnosed with VTE during hospitalization for COVID-19. The majority of patients were receiving thromboprophylaxis at the time of VTE diagnosis, and the early mortality rate was relatively low overall but higher in ICU patients. Further studies are needed to determine optimal strategies for preventing VTE and reducing adverse outcomes in these patients.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2021)
Article
Hematology
Farid Rashidi, Stefano Barco, Farin Kamangar, Gustavo A. Heresi, Ashkan Emadi, Cihangir Kaymaz, Pavel Jansa, Abilio Reis, Arash Rashidi, Ali Taghizadieh, Parisa Rezaeifar, Minoosh Moghimi, Samad Ghodrati, Abolfazl Mozafari, Ali Alavi Foumani, Ouria Tahamtan, Effat Rafiee, Zahra Abbaspour, Kasra Khodadadi, Golsa Alamdari, Yasman Boodaghi, Maryam Rezaei, Muhammad Javad Muhammadi, Meysam Abbasi, Fatemeh Movaseghi, Ata Koohi, Leila Shakourzad, Fatemeh Ebrahimi, Sarvin Radvar, Maryam Amoozadeh, Fatemeh Fereidooni, Hanieh Naseari, Kobra Movalled, Ozra Ghorbani, Khalil Ansarin
Summary: The rate of symptomatic VTE in COVID-19 patients after hospital discharge is not high, suggesting that routine extended thromboprophylaxis may not provide a net clinical benefit. Randomized trials are needed to further investigate this conclusion.
THROMBOSIS RESEARCH
(2021)
Article
Emergency Medicine
Adam D. Klotz, Jeffrey M. Caterino, Danielle Durham, Juan Felipe Rico, Daniel J. Pallin, Corita R. Grudzen, Caroline McNaughton, Isabelle Marcelin, Beau Abar, David Adler, Aveh Bastani, Steven L. Bernstein, Jason J. Bischof, Christopher J. Coyne, Daniel J. Henning, Matthew F. Hudson, Gary H. Lyman, Troy E. Madsen, Cielito C. Reyes-Gibby, Richard J. Ryan, Nathan Shapiro, Robert Swor, Charles R. Thomas, Arvind Venkat, Jason Wilson, Sai-Ching Jim Yeung, Sule Yilmaz, Robin Stutman, Christopher W. Baugh
Summary: In this study comparing cancer patients who received observation unit care with those admitted to the hospital from the emergency department, it was found that there may be underutilization of observation unit care, highlighting a potential target for improvement in healthcare processes.
ACADEMIC EMERGENCY MEDICINE
(2022)
Editorial Material
Oncology
Gary H. Lyman, Pavlos Msaouel, Nicole M. Kuderer
Summary: This article summarizes key considerations related to risk modeling in clinical oncology, including data quality, missing data, sample size estimation, and variable selection. The importance of rigorous internal validation and careful examination of model stability and quality is emphasized.
CANCER INVESTIGATION
(2023)
Review
Oncology
Nicole M. Kuderer, Aakash Desai, Maryam B. Lustberg, Gary H. Lyman
Summary: Despite the rise of novel targeted agents and immunotherapies, chemotherapy remains the primary treatment for most human malignancies. However, chemotherapy-associated adverse events (CAAEs) have a significant impact on patients' physical, emotional, and social well-being. Efforts to identify and summarize management approaches for CAAEs are currently limited. This review focuses on the most common acute CAAEs that affect survival, quality of life, function, and continuation of optimal therapy, providing insights into their underlying causes, evidence-based treatments, prevention strategies, and management recommendations.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Oncology
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Summary: In the past decade, there have been multiple trials to determine the effectiveness of treating cancer based on specific genomic alterations. However, most patients do not respond to single-agent therapies targeting a single alteration, and drug resistance often develops. To address this, the NCI has developed NCI-ComboMATCH, a study to explore genomically-directed combination therapies and overcome drug resistance.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Gary H. Lyman
CANCER INVESTIGATION
(2023)
Article
Oncology
Ramon Mohanlal, Stephan Ogenstad, Gary H. Lyman, Lan Huang, Douglas W. Blayney
Summary: Neutropenia caused by myelosuppressive cancer chemotherapy is a significant toxicity, and grade 4 neutropenia (Gr4N) is a measure of its severity. Through a meta-analysis, we found that the incidence of Gr4N is closely correlated with febrile neutropenia (FN), days of severe neutropenia (DSN), and nadir absolute neutrophil count (ANC), all of which are important predictors of morbidity. By setting a threshold of 65% for Gr4N, the risks of FN and DSN were below the levels for adverse CIN outcomes. Gr4N is highly predictive for adverse CIN outcomes, and a 65% threshold distinguishes between low and high risks for FN and other adverse CIN outcomes.
CANCER INVESTIGATION
(2023)
Review
Oncology
Maryam B. Lustberg, Nicole M. Kuderer, Aakash Desai, Cristiane Bergerot, Gary H. Lyman
Summary: Despite the lack of systematic efforts, this review provides a comprehensive analysis of the most common long-term and late adverse events associated with chemotherapy and other anticancer treatments. It discusses the underlying mechanisms, management strategies, and clinical practice guidelines for these adverse events. Additionally, it highlights the need for effective management of treatment-related events in oncology.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Oncology
Brian Bourbeau, Gary H. Lyman, Xiudong Jennifer Lei, Lee Jones, Jon Rosenthal, Mary May Kozlik, Kurt R. Oettel, Alfred Tinger, Ray Page
Summary: Biosimilars have increased in usage over the past 3 years, with utilization rates ranging from 51% to 80% depending on the specific biologic. Independent physician practices had higher utilization of biosimilars for certain biologics, while Medicaid plans and traditional Medicare had lower utilization rates compared to commercial health plans. The average cost per dose decreased by 24% to 41% for the studied biologics.
JCO ONCOLOGY PRACTICE
(2023)
Article
Oncology
Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, Fatima Cardoso, Zeina Nahleh, Julie M. Vose, Julie R. Gralow, Michael Francisco, Shimere Sherwood
Summary: ASCO has taken steps to raise awareness about biosimilar products and published a statement in 2018 to provide guidance on their use in oncology. The FDA has approved a significant number of biosimilar products for use in the United States, including those for cancer treatment. The recent approval of interchangeable biosimilar products for various diseases has further expanded the market. This policy statement by ASCO proposes recommendations on value, interchangeability, clinician barriers, and patient education and access to guide their future activities.
JCO ONCOLOGY PRACTICE
(2023)
Editorial Material
Oncology
Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)
Article
Oncology
Samuel M. Rubinstein, Divaya Bhutani, Ryan C. Lynch, Chih-Yuan Hsu, Yu Shyr, Shailesh Advani, Ruben A. Mesa, Sanjay Mishra, Daniel P. Mundt, Dimpy P. Shah, R. Alejandro Sica, Keith E. Stockerl-Goldstein, Catherine Stratton, Matthias Weiss, Alicia Beeghly-Fadiel, Melissa Accordino, Sarit E. Assouline, Joy Awosika, Ziad Bakouny, Babar Bashir, Stephanie Berg, Mehmet Asim Bilen, Cecilia A. Castellano, Jacob C. Cogan, K. C. Devendra, Christopher R. Friese, Shilpa Gupta, Daniel Hausrath, Clara Hwang, Nathalie A. Johnson, Monika Joshi, Anup Kasi, Elizabeth J. Klein, Vadim S. Koshkin, Nicole M. Kuderer, Daniel H. Kwon, Chris Labaki, Tahir Latif, Eric Lau, Xuanyi Li, Gary H. Lyman, Rana R. McKay, Gayathri Nagaraj, Amanda Nizam, Taylor K. Nonato, Adam J. Olszewski, Hyma Polimera, Andrew J. Portuguese, Matthew M. Puc, Pedram Razavi, Rachel Rosovski, Andrew Schmidt, Sumit A. Shah, Aditi Shastri, Christopher Su, Pallawi Torka, Trisha M. Wise-Draper, Leyre Zubiri, Jeremy L. Warner, Michael A. Thompson
Summary: Patients with B-lymphoid malignancies, especially those who have received recent anticancer therapy, are at a uniquely high risk of severe COVID-19.
BLOOD CANCER DISCOVERY
(2022)
Article
Hematology
E. O. Artemenko, S. I. Obydennyi, K. S. Troyanova, G. A. Novichkova, D. Y. Nechipurenko, M. A. Panteleev
Summary: In this study, we investigated the adhesive properties of circulating plasma-derived and platelet-derived microvesicles (MVs) and their potential role in thrombus growth. The results showed that both types of MVs weakly bound fibrinogen but did not stably adhere to immobilized fibrinogen. Moreover, the presence of these MVs did not significantly affect thrombus formation. Therefore, MVs present in the plasma of healthy individuals are unlikely to directly contribute to thrombus formation under arterial flow conditions.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J. Favaloro
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marium Malik, Maha Al-Ghafry, Abraham Haimed, Julia Su, Maribel Lema, Linda Shore-Lessersson, Suchitra S. Acharya
Summary: This study analyzed and evaluated leukemia-associated coagulopathy in newly diagnosed pediatric leukemia patients using CCTs and ROTEM. The results showed that fibrinogen and platelets played a significant role in causing coagulopathies in this population. This suggests the utility of using CCTs and ROTEM in the pediatric population to evaluate hemostatic function and guide blood product replacement.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Mohammad M. Elahi, Alexandra N. Witt, Edward L. G. Pryzdial, Paul B. McBeth
Summary: Thrombotic disease may be underdiagnosed in microgravity conditions, and the underlying factors are still poorly understood. A case of internal jugular vein thrombosis was recently diagnosed in a low-risk female astronaut, and six out of ten additional crew members showed risk factors for jugular venous flow. Observations in space and studies on Earth suggest that microgravity affects blood flow, coagulation, and vascular function.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Stian Ingemann-Molden, Christina Krogner Caspersen, Nanna Rolving, Anette Arbjerg Hojen, Frederikus A. Klok, Erik L. Grove, Barbara Cristina Brocki, Jane Andreasen
Summary: This study found that no single PROM covered all aspects considered important by PE patients. PROMs recommended in the ICHOM core set covered most aspects, but worrisome thoughts, hypervigilance around symptoms, and uncertainty of illness were not covered.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Haomin Yan, Tsutomu Sasaki, Yasufumi Gon, Kumiko Nishiyama, Hideaki Kanki, Hideki Mochizuki
Summary: The incidence of cancer-associated stroke has increased with the prolonged survival times of cancer patients. In this study, the researchers focused on the driver gene KRAS and found that KRAS mutations exacerbated neurological deficits after stroke and promoted tumor growth. They also identified the upregulation of pro-inflammatory responses and the promotion of STAT3 phosphorylation in mice with KRAS mutations. Additionally, the researchers found that colorectal cancer patients with stroke onset within 3 months after cancer diagnosis had a worse prognosis.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Tomoki Togashi, Satomi Nagaya, Makiko Meguro-Horike, Haruto Matsumoto, Yuta Imai, Koichi Yamaguchi, Yoshinari Fujii, Haruka Moriya, Yuika Kikuchi, Ibuki Yasuda, Shin-ichi Horike, Eriko Morishita
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marta Najarro, Winnifer Briceno, Carmen Rodriguez, Alfonso Muriel, Sara Gonzalez, Ana Castillo, Ignacio Jara, Parth Rali, Catalin Toma, Behnood Bikdeli, David Jimenez
Summary: The CPES score is a useful tool in identifying the risk of hemodynamic deterioration in normotensive patients with acute PE, with acceptable C-statistic, excellent specificity, and low positive predictive value.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Lei Liu, Huifang Xu, Jian Wang, Haiyan Wang, Saisai Ren, Qian Huang, Mingyan Zhang, Hui Zhou, Chunyan Yang, Lu Jia, Yu Huang, Hao Zhang, Yanling Tao, Ying Li, Yanan Min
Summary: This study investigated the gut microbiota metabolites and cytokines, chemokines, and growth factors in patients with ITP and found their association with treatment responsiveness. The findings suggest that imbalanced secretion of cyto(chemo)kins/growth factors and inadequate levels of TMAO are characteristic of patients with ITP.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Roxanne Mcknight, Mohammad Salameh, Lee Ann Jones, Greta Anton, Lindsay Carter
Summary: This study evaluated the safety of fixed-dose heparin titration boluses in underweight patients with VTE. The results showed that although underweight patients required more frequent holding of heparin, there was no significant increase in bleeding risk.
THROMBOSIS RESEARCH
(2024)